PMPaula J. Martinez

Paula J. Martinez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paula J. Martinez has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension

    by Marta Martin-Lorenzo, Paula J. Martinez, Montserrat Baldan-Martin, Juan A. Lopez, Pablo Minguez, Aranzazu Santiago-Hernandez, Jesus Vazquez, Julian Segura, Gema Ruiz-Hurtado, Fernando Vivanco, et al.

    Resistant hypertension prevalence is progressively increasing, and prolonged exposure to suboptimal blood pressure control results in higher cardiovascular risk and end-organ damage. Among various antihypertensive agents, spironolactone seems the most effective choice to treat resistant hypertension once triple therapy including a diuretic fails. However success in blood pressure control is not guaranteed, adverse effects are not negligible, and no clinical tools are available to predict patient’s response. Complementary to our previous study of resistant hypertension metabolism, here we investigated urinary proteome changes with potential capacity to predict response to spironolactone. Twenty-nine resistant hypertensives were included. A prospective study was conducted and basal urine was collected before spironolactone administration. Patients were classified in responders or nonresponders in terms of blood pressure control. Protein quantitation was performed by liquid chromatography–mass spectrometry; ELISA and target mass spectrometry analysis were performed for confirmation. Among 3310 identified proteins, HP (haptoglobin) and HPR (haptoglobin-related protein) showed the most significant variations, with increased levels in nonresponders compared with responders before drug administration (variation rate, 5.98 and 7.83, respectively). Protein-coordinated responses were also evaluated by functional enrichment analysis, finding oxidative stress, chronic inflammatory response, blood coagulation, complement activation, and regulation of focal adhesions as physiopathological mechanisms in resistant hypertension. In conclusion, protein changes able to predict patients’ response to spironolactone in basal urine were here identified for the first time. These data, once further confirmed, will support clinical decisions on patients’ management while contributing to optimize the rate of control of resistant hypertensives with spironolactone.


  • Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention

    by Paula J. Martínez, Montserrat Baldán-Martín, Juan A. López, Marta Martín-Lorenzo, Aránzazu Santiago-Hernández, Marta Agudiez, Martha Cabrera, Eva Calvo, Jesús Vázquez, Gema Ruiz-Hurtado, et al.


  • Open Access

    Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals

    by Montserrat Baldan-Martin, Juan A. Lopez, Nerea Corbacho-Alonso, Paula J. Martinez, Elena Rodriguez-Sanchez, Laura Mourino-Alvarez, Tamara Sastre-Oliva, Tatiana Martin-Rojas, Raul Rincón, Eva Calvo, et al.

    The evaluation of cardiovascular (CV) risk is based on equations derived from epidemiological data in individuals beyond the limits of middle age such as the Framingham and SCORE risk assessments. Lifetime Risk calculator (QRisk®), estimates CV risk throughout a subjects’ lifetime, allowing those. A more aggressive and earlier intervention to be identified and offered protection from the consequences of CV and renal disease. The search for molecular profiles in young people that allow a correct stratification of CV risk would be of great interest to adopt preventive therapeutic measures in individuals at high CV risk. To improve the selection of subjects susceptible to intervention with aged between 30–50 years, we have employed a multiple proteomic strategy to search for new markers of early CV disease or reported CV events and to evaluate their relationship with Lifetime Risk. Blood samples from 71 patients were classified into 3 groups according to their CV risk (healthy, with CV risk factors and with a previously reported CV event subjects) and they were analyzed using a high through quantitative proteomics approach. This strategy allowed three different proteomic signatures to be defined, two of which were related to CV stratification and the third one involved markers of organ damage.


  • Open Access

    Author Correction: Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria

    by Marta Martin-Lorenzo, Laura Gonzalez-Calero, Paula J. Martinez, Montserrat Baldan-Martin, Juan Antonio Lopez, Gema Ruiz-Hurtado, Fernando de la Cuesta, Julián Segura, Jesús Vazquez, Fernando Vivanco, et al.

    A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.


  • Citric Acid Metabolism in Resistant Hypertension

    by Marta Martin-Lorenzo, Paula J. Martinez, Montserrat Baldan-Martin, Gema Ruiz-Hurtado, Jose Carlos Prado, Julian Segura, Fernando de la Cuesta, Maria G. Barderas, Fernando Vivanco, Luis Miguel Ruilope, et al.

    Resistant hypertension (RH) affects 9% to 12% of hypertensive adults. Prolonged exposure to suboptimal blood pressure control results in end-organ damage and cardiovascular risk. Spironolactone is the most effective drug for treatment, but not all patients respond and side effects are not negligible. Little is known on the mechanisms responsible for RH. We aimed to identify metabolic alterations in urine. In addition, a potential capacity of metabolites to predict response to spironolactone was investigated. Urine was collected from 29 patients with RH and from a group of 13 subjects with pseudo-RH. For patients, samples were collected before and after spironolactone administration and were classified in responders (n=19) and nonresponders (n=10). Nuclear magnetic resonance was applied to identify altered metabolites and pathways. Metabolites were confirmed by liquid chromatography-mass spectrometry. Citric acid cycle was the pathway most significantly altered ( P <0.0001). Metabolic concentrations were quantified and ranged from ng/mL malate to μg/mL citrate. Citrate and oxaloacetate increased in RH versus pseudoresistant. Together with α-ketoglutarate and malate, they were able to discriminate between responders and nonresponders, being the 4 metabolites increased in nonresponders. Combined as a prediction panel, they showed receiver operating characteristiccurve with area under the curve of 0.96. We show that citric acid cycle and deregulation of reactive oxygen species homeostasis control continue its activation after hypertension was developed. A metabolic panel showing alteration before spironolactone treatment and predicting future response of patients is shown. These molecular indicators will contribute optimizing the rate of control of RH patients with spironolactone.


  • Open Access

    Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria

    by Marta Martin-Lorenzo, Laura Gonzalez-Calero, Paula J. Martinez, Montserrat Baldan-Martin, Juan Antonio Lopez, Gema Ruiz-Hurtado, Fernando de la Cuesta, Julián Segura, Jesús Vazquez, Fernando Vivanco, et al.

    Albuminuria development in hypertensive patients is an indicator of higher cardiovascular (CV) risk and renal damage. Chronic renin-angiotensin system (RAS) suppression facilitates blood pressure control but it does not prevent from albuminuria development. We pursued the identification of protein indicators in urine behind albuminuria development in hypertensive patients under RAS suppression. Urine was collected from 100 patients classified in three groups according to albuminuria development: (a) patients with persistent normoalbuminuria; (b) patients developing de novo albuminuria; (c) patients with maintained albuminuria. Quantitative analysis was performed in a first discovery cohort by isobaric labeling methodology. Alterations of proteins of interest were confirmed by target mass spectrometry analysis in an independent cohort. A total of 2416 proteins and 1223 functional categories (coordinated protein responses) were identified. Immune response, adhesion of immune and blood cells, and phagocytosis were found significantly altered in patients with albuminuria compared to normoalbuminuric individuals. The complement system C3 increases, while Annexin A1, CD44, S100A8 and S100A9 proteins showed significant diminishment in their urinary levels when albuminuria is present. This study reveals specific links between immune response and controlled hypertension in patients who develop albuminuria, pointing to potential protein targets for novel and future therapeutic interventions.


  • Open Access

    Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria

    by Laura Gonzalez-Calero, Paula J. Martínez, Marta Martin-Lorenzo, Montserrat Baldan-Martin, Gema Ruiz-Hurtado, Fernando de la Cuesta, Eva Calvo, Julian Segura, Juan Antonio Lopez, Jesús Vázquez, et al.

    Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria


  • Hypertensive patients exhibit an altered metabolism. A specific metabolite signature in urine is able to predict albuminuria progression

    by Laura Gonzalez-Calero, Marta Martin-Lorenzo, Paula J. Martínez, Montserrat Baldan-Martin, Gema Ruiz-Hurtado, Julian Segura, Fernando de la Cuesta, Maria G. Barderas, Luis M. Ruilope, Fernando Vivanco, et al.


  • Cytoskeleton deregulation and impairment in amino acids and energy metabolism in early atherosclerosis at aortic tissue with reflection in plasma

    by Marta Martin-Lorenzo, Laura Gonzalez-Calero, Aroa S. Maroto, Paula J. Martinez, Irene Zubiri, Fernando de la Cuesta, Laura Mourino-Alvarez, Maria G. Barderas, Angeles Heredero, Gonzalo Aldamiz-Echevarría, et al.